Research into new therapies for lymphoma is fast-paced, with new developments taking place all the time, so it is important for clinicians and healthcare professionals within the field to keep up to date with the latest evidence. Advances in the Treatment of Lymphoma will examine the current and emerging treatments for the different types of lymphoma, with the aim of updating knowledge and arming participants with practical information that can positively influence every day clinical practice.

Benefits of attending Advances in the Treatment of Lymphoma: • Hear updates about new research and clinical trials, including targeted personalised therapies • Evaluate the current treatment strategies for Hodgkin’s and non-Hodgkin’s lymphoma and refractory lymphoma • Gain insights into optimising patient care, including long-term follow up care and palliative care • Take part in treatment case studies on optimal management of Hodgkin’s, B-cell and T-cell lymphoma • Share and exchange ideas with the leading practitioners in the field

Who should attend? Advances in the Treatment of Lymphoma will be of particular interest to the following: • Haemato-oncologists • Haematologists • Clinical oncologists • Haematopathologists • Clinical immunologists • Specialists in transplantation • Nurse specialists and nurse practitioners in haematology, oncology and transplantation • Researchers in haematology, oncology and immunology • All trainees in these disciplines

Dr Andrew Davies

Professor Ray Powles (CBE)

Dr Graham Collins

Dr Chris Hatton

Dr Ruth Pettengell

Dr Paul Fields

Dr Claire Dearden

Dr Robert Marcus

Dr Karl Peggs (tbc)

Dr Alastair Smith

Dr Martin Howard